Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Bone Marrow Transplantation

  Free Subscription


Articles published in Biol Blood Marrow Transplant

Retrieve available abstracts of 52 articles:
HTML format
Text format



Single Articles


    February 2017
  1. MIYAMOTO T, Fukuda T, Nakashima M, Henzan T, et al
    Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Unrelated Allogeneic Bone Marrow Transplantation Facilitated by the Japan Marrow Donor Program.
    Biol Blood Marrow Transplant. 2017 Feb 17. pii: S1083-8791(17)30281.
    PubMed     Text format     Abstract available


    January 2017
  2. CHEN YB, Efebera YA, Johnston L, Ball ED, et al
    Increased Foxp3+Helios+ Regulatory T Cells and Decreased Acute Graft-Versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells.
    Biol Blood Marrow Transplant. 2017 Jan 16. pii: S1083-8791(17)30194.
    PubMed     Text format     Abstract available


  3. MAJZNER RG, Mogri H, Varadhan R, Brown P, et al
    Post-Transplant Cyclophosphamide after Bone Marrow Transplantation is Not Associated with an Increased Risk of Donor Derived Malignancy.
    Biol Blood Marrow Transplant. 2017 Jan 3. pii: S1083-8791(17)30065.
    PubMed     Text format     Abstract available


    November 2016
  4. KLEIN OR, Buddenbaum J, Tucker N, Chen AR, et al
    Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies.
    Biol Blood Marrow Transplant. 2016 Nov 22. pii: S1083-8791(16)30516.
    PubMed     Text format     Abstract available


  5. YOKOYAMA H, Kanda J, Fuji S, Kim SW, et al
    Impact of HLA allele mismatch in unrelated bone marrow transplantation with reduced intensity conditioning regimen.
    Biol Blood Marrow Transplant. 2016 Nov 11. pii: S1083-8791(16)30487.
    PubMed     Text format     Abstract available


  6. BONFIM C, Ribeiro L, Nichele S, Loth G, et al
    Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Children and Adolescents with Fanconi Anemia.
    Biol Blood Marrow Transplant. 2016 Nov 7. pii: S1083-8791(16)30484.
    PubMed     Text format     Abstract available


    October 2016
  7. PATTON WN, Nivison-Smith I, Bardy P, Dodds A, et al
    Graft Transit Time Has No Effect on Outcome of Unrelated Donor Haematopoietic Cell Transplants Performed in Australia and New Zealand: a Study From the Australasian Bone Marrow Transplant Recipient Registry.
    Biol Blood Marrow Transplant. 2016 Oct 4. pii: S1083-8791(16)30389.
    PubMed     Text format     Abstract available


    July 2016
  8. KUWATSUKA Y, Kanda J, Yamazaki H, Mori T, et al
    A Comparison of Outcomes for Cord Blood Transplant and Unrelated Bone Marrow Transplant in Adult Aplastic Anemia.
    Biol Blood Marrow Transplant. 2016 Jul 8. pii: S1083-8791(16)30210.
    PubMed     Text format     Abstract available


    June 2016
  9. KHAN NE, Rosenberg PS, Alter BP
    Preemptive Bone Marrow Transplantation and Event-Free Survival in Fanconi Anemia.
    Biol Blood Marrow Transplant. 2016 Jun 21. pii: S1083-8791(16)30175.
    PubMed     Text format     Abstract available


    May 2016
  10. KUMAR R, Kimura F, Ahn KW, Hu ZH, et al
    Comparing Outcomes with Bone Marrow or Peripheral Blood Stem Cells as Graft Source for Matched Sibling Transplants in Severe Aplastic Anemia across Different Economic Regions.
    Biol Blood Marrow Transplant. 2016;22:932-40.
    PubMed     Text format     Abstract available


    April 2016
  11. LANGE S, Steder A, Glass A, Killian D, et al
    Low Radiation Dose and Low Cell Dose Increase the Risk of Graft Rejection in a Canine Hematopoietic Stem Cell Transplantation Model.
    Biol Blood Marrow Transplant. 2016;22:637-43.
    PubMed     Text format     Abstract available


  12. KANDA J, Brazauskas R, Hu ZH, Kuwatsuka Y, et al
    Graft-versus-Host Disease after HLA-Matched Sibling Bone Marrow or Peripheral Blood Stem Cell Transplantation: Comparison of North American Caucasian and Japanese Populations.
    Biol Blood Marrow Transplant. 2016;22:744-51.
    PubMed     Text format     Abstract available


  13. MERKEL EC, Mitchell SA, Lee SJ
    Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews.
    Biol Blood Marrow Transplant. 2016;22:752-8.
    PubMed     Text format     Abstract available


  14. BUCK K, Wadsworth K, Setterholm M, Maiers M, et al
    High-Resolution Match Rate of 7/8 and 9/10 or Better for the Be The Match Unrelated Donor Registry.
    Biol Blood Marrow Transplant. 2016;22:759-63.
    PubMed     Text format     Abstract available


    March 2016
  15. REDDY P, Cutler C
    Selected Reviews from the 2016 BMT Tandem Meetings.
    Biol Blood Marrow Transplant. 2016;22.
    PubMed     Text format    


    February 2016
  16. TERAKURA S, Atsuta Y, Tsukada N, Kobayashi T, et al
    Comparison of Outcomes of 8/8 and 7/8 Allele-Matched Unrelated Bone Marrow Transplantation and Single-Unit Cord Blood Transplantation in Adults with Acute Leukemia.
    Biol Blood Marrow Transplant. 2016;22:330-8.
    PubMed     Text format     Abstract available


  17. YOUNG JA, Logan BR, Wu J, Wingard JR, et al
    Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors.
    Biol Blood Marrow Transplant. 2016;22:359-70.
    PubMed     Text format     Abstract available


  18. GUIEZE R, Damaj G, Pereira B, Robin M, et al
    Management of Myelodysplastic Syndrome Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation: A Study by the French Society of Bone Marrow Transplantation and Cell Therapies.
    Biol Blood Marrow Transplant. 2016;22:240-7.
    PubMed     Text format     Abstract available


    January 2016
  19. JACOBY E, Chen A, Loeb DM, Gamper CJ, et al
    Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen-Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies.
    Biol Blood Marrow Transplant. 2016;22:112-8.
    PubMed     Text format     Abstract available


    December 2015
  20. DYER G, Gilroy N, Brown L, Hogg M, et al
    What They Want: Inclusion of Bone Marrow Transplantation Survivor Preference in the Development of Models of Care for Long-Term Health in Sydney, Australia.
    Biol Blood Marrow Transplant. 2015 Dec 30. pii: S1083-8791(15)01914.
    PubMed     Text format     Abstract available


  21. LIU J, Guo YM, Onai N, Ohyagi H, et al
    CpG-ODN exacerbates hemophagocytosis by inducing TNF-alpha production in mice following bone marrow transplantation.
    Biol Blood Marrow Transplant. 2015 Dec 28. pii: S1083-8791(15)01913.
    PubMed     Text format     Abstract available


    October 2015
  22. BAYRAKTAR UD, Milton DR, Guindani M, Rondon G, et al
    Optimal Threshold and Time of Absolute Lymphocyte Count Assessment for Outcome Prediction after Bone Marrow Transplantation.
    Biol Blood Marrow Transplant. 2015 Oct 30. pii: S1083-8791(15)00709.
    PubMed     Text format     Abstract available


    September 2015
  23. CHUNG CP, Sargent RE, Chung NT, Lacey JV Jr, et al
    Graft-Versus-Host Disease-Associated Vulvovaginal Symptoms after Bone Marrow Transplantation.
    Biol Blood Marrow Transplant. 2015 Sep 29. pii: S1083-8791(15)00646.
    PubMed     Text format     Abstract available


    July 2015
  24. KHAN NE, Rosenberg PS, Lehmann HP, Alter BP, et al
    Preemptive Bone Marrow Transplantation for FANCD1/BRCA2.
    Biol Blood Marrow Transplant. 2015 Jul 13. pii: S1083-8791(15)00462.
    PubMed     Text format     Abstract available


  25. KANAKRY JA, Gocke CD, Bolanos-Meade J, Gladstone DE, et al
    Phase II study of non-myeloablative allogeneic bone marrow transplantation for B-cell lymphoma with post-transplantation rituximab and donor selection based first on non-HLA factors.
    Biol Blood Marrow Transplant. 2015 Jul 13. pii: S1083-8791(15)00468.
    PubMed     Text format     Abstract available


  26. JAIN A, Sahdev I
    Alemtuzumab Pharmacokinetics in Hematopoietic Stem Cell Transplants for Nonmalignant Genetic Diseases.
    Biol Blood Marrow Transplant. 2015;21:1337.
    PubMed     Text format    


  27. WU Y, Bastian D, Schutt S, Nguyen H, et al
    Essential Role of Interleukin-12/23p40 in the Development of Graft-versus-Host Disease in Mice.
    Biol Blood Marrow Transplant. 2015;21:1195-204.
    PubMed     Text format     Abstract available


  28. CARPENTER PA, Kitko CL, Elad S, Flowers ME, et al
    National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report.
    Biol Blood Marrow Transplant. 2015;21:1167-87.
    PubMed     Text format     Abstract available


  29. GONCALVES MV, Yamamoto M, Kimura EY, Colturato VA, et al
    Low Counts of Plasmacytoid Dendritic Cells after Engraftment Are Associated with High Early Mortality after Allogeneic Stem Cell Transplantation.
    Biol Blood Marrow Transplant. 2015;21:1223-9.
    PubMed     Text format     Abstract available


    June 2015
  30. HOLTAN SG, Verneris MR, Schultz KR, Newell LF, et al
    Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802.
    Biol Blood Marrow Transplant. 2015;21:1029-36.
    PubMed     Text format     Abstract available


  31. BOQUETT J, Schuler-Faccini L, Jobim LF, Jobim M, et al
    Self-assessment of color categories and its relationship with HLA profiling in Brazilian bone marrow donors.
    Biol Blood Marrow Transplant. 2015;21:1140-4.
    PubMed     Text format     Abstract available


  32. ZILBERBERG J, Feinman R, Korngold R
    Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation.
    Biol Blood Marrow Transplant. 2015;21:1000-7.
    PubMed     Text format     Abstract available


    April 2015
  33. TOUBAI T, Mathewson N, Oravecz-Wilson K, Reddy P, et al
    Host CD8alpha+ dendritic cells may be a key factor for separating graft-versus-host disease from graft-versus-leukemia.
    Biol Blood Marrow Transplant. 2015;21:775-6.
    PubMed     Text format    


    March 2015
  34. TRUELOVE E, Fox C, Robinson S, Pearce R, et al
    Carmustine, etoposide, cytarabine, and melphalan (BEAM)-campath allogeneic stem cell transplantation for aggressive non-hodgkin lymphoma: an analysis of outcomes from the British Society of Blood and Marrow Transplantation.
    Biol Blood Marrow Transplant. 2015;21:483-8.
    PubMed     Text format     Abstract available


  35. MAHADEO KM, Weinberg KI, Abdel-Azim H, Miklos DB, et al
    A reduced-toxicity regimen is associated with durable engraftment and clinical cure of nonmalignant genetic diseases among children undergoing blood and marrow transplantation with an HLA-matched related donor.
    Biol Blood Marrow Transplant. 2015;21:440-4.
    PubMed     Text format     Abstract available


    February 2015
  36. DAVIS JE, Harvey M, Gherardin NA, Koldej R, et al
    A radio-resistant perforin-expressing lymphoid population controls allogeneic T cell engraftment, activation, and onset of graft-versus-host disease in mice.
    Biol Blood Marrow Transplant. 2015;21:242-9.
    PubMed     Text format     Abstract available


  37. BILLEN A, Madrigal JA, Strydom A, Szydlo RM, et al
    Predonation health-related quality of life scores predict time to recovery in hematopoietic stem cell donors.
    Biol Blood Marrow Transplant. 2015;21:350-6.
    PubMed     Text format     Abstract available


  38. APPELBAUM FR, Anasetti C, Antin JH, Atkins H, et al
    Blood and marrow transplant clinical trials network state of the Science Symposium 2014.
    Biol Blood Marrow Transplant. 2015;21:202-24.
    PubMed     Text format    


  39. ARAI S, Arora M, Wang T, Spellman SR, et al
    Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research.
    Biol Blood Marrow Transplant. 2015;21:266-74.
    PubMed     Text format     Abstract available


  40. GREIN CAVALCANTI L, Fuentes Araujo RL, Bonfim C, Torres-Pereira CC, et al
    Oral manifestations compatible with chronic graft-versus-host disease in patients with Fanconi anemia.
    Biol Blood Marrow Transplant. 2015;21:275-80.
    PubMed     Text format     Abstract available


  41. HASHMI S, Carpenter P, Khera N, Tichelli A, et al
    Lost in transition: the essential need for long-term follow-up clinic for blood and marrow transplantation survivors.
    Biol Blood Marrow Transplant. 2015;21:225-32.
    PubMed     Text format     Abstract available


  42. KOMANDURI KV, Veys P
    Selected reviews from the 2015 BMT tandem meetings.
    Biol Blood Marrow Transplant. 2015;21.
    PubMed     Text format    


    January 2015
  43. KOLB HJ
    As time goes by...
    Biol Blood Marrow Transplant. 2015;21:1-2.
    PubMed     Text format    


  44. RADHAKRISHNAN SV, Palaniyandi S, Mueller G, Miklos S, et al
    Preventive azithromycin treatment reduces noninfectious lung injury and acute graft-versus-host disease in a murine model of allogeneic hematopoietic cell transplantation.
    Biol Blood Marrow Transplant. 2015;21:30-8.
    PubMed     Text format     Abstract available


  45. O'DONNELL P, Raj K, Pagliuca A
    High fever occurring 4 to 5 days post-transplant of haploidentical bone marrow or peripheral blood stem cells after reduced-intensity conditioning associated with the use of post-transplant cyclophosphamide as prophylaxis for graft-versus-host disease
    Biol Blood Marrow Transplant. 2015;21:197-8.
    PubMed     Text format    


  46. DEHN J, Buck K, Maiers M, Confer D, et al
    8/8 and 10/10 high-resolution match rate for the be the match unrelated donor registry.
    Biol Blood Marrow Transplant. 2015;21:137-41.
    PubMed     Text format     Abstract available


  47. HOWARD CA, Fernandez-Vina MA, Appelbaum FR, Confer DL, et al
    Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: consensus opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).
    Biol Blood Marrow Transplant. 2015;21:4-7.
    PubMed     Text format     Abstract available


  48. EAPEN M, Logan BR, Appelbaum FR, Antin JH, et al
    Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy.
    Biol Blood Marrow Transplant. 2015;21:55-9.
    PubMed     Text format     Abstract available


    October 2014
  49. CHARRIER E, Cordeiro P, Brito RM, Harnois M, et al
    Impaired interferon-alpha production by plasmacytoid dendritic cells after cord blood transplantation in children: implication for post-transplantation toll-like receptor ligand-based immunotherapy.
    Biol Blood Marrow Transplant. 2014;20:1501-7.
    PubMed     Text format     Abstract available


  50. KANAKRY CG, Luznik L
    Are alternative donors really still "alternative?".
    Biol Blood Marrow Transplant. 2014;20:1463-4.
    PubMed     Text format    


  51. EAPEN M, O'Donnell P, Brunstein CG, Wu J, et al
    Mismatched related and unrelated donors for allogeneic hematopoietic cell transplantation for adults with hematologic malignancies.
    Biol Blood Marrow Transplant. 2014;20:1485-92.
    PubMed     Text format     Abstract available


  52. SCHMID PM, Bouazzaoui A, Doser K, Schmid K, et al
    Endothelial dysfunction and altered mechanical and structural properties of resistance arteries in a murine model of graft-versus-host disease.
    Biol Blood Marrow Transplant. 2014;20:1493-500.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bone Marrow Transplantation is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: